EMBO

Proxygen Announces Formation of Scientific Advisory Board

Retrieved on: 
Wednesday, November 15, 2023

VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB). The newly appointed SAB, which is comprised of highly regarded thought leaders in the emerging field of protein degradation, will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. In addition to its internal programs, Proxygen is also actively engaged in strategic research collaboration and license agreements with Merck & Co (known as MSD outside the U.S. and Canada), Boehringer Ingelheim and Merck KGaA designed to jointly identify and develop novel molecular glue degraders.

Key Points: 
  • SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine
    VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB).
  • Schulman and Draetta to the Proxygen team as key advisors and pair them with Drs.
  • Winter and Kubicek, who co-founded the company, based on their trailblazing research at CeMM,” said Bernd Boidol, Ph.D., chief executive officer of Proxygen.
  • By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine.

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

Retrieved on: 
Tuesday, November 28, 2023

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).
  • First organized in 1960, ASCB is an international organization of cell biologists dedicated to advancing scientific discovery, advocating sound research policies, improving education, promoting professional development and increasing diversity in the scientific workforce.
  • The Membership Committee is responsible for implementing programs and services to meet the needs of the ASCB’s membership and support its mission and strategic plan, including recruiting new members and retaining current members.
  • Aimed at students, post-docs and research scientists, the roundtable will be held Dec. 3, 2023, at 1:15 p.m.

Culture Biosciences Appoints Darcy Birse as Chief Commercial Officer

Retrieved on: 
Wednesday, September 13, 2023

South San Francisco, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences , a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy Birse as the company's new Chief Commercial Officer (CCO).

Key Points: 
  • South San Francisco, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences , a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy Birse as the company's new Chief Commercial Officer (CCO).
  • Darcy will lead the company's commercial strategy and drive growth initiatives to further strengthen Culture's position as a leader in the bioprocessing industry.
  • With a career spanning over 30 years in the life sciences sector, Darcy brings a wealth of global experience in Commercial Leadership, Marketing, Sales and Business Development to Culture Biosciences.
  • "As we continue to expand our presence in the bioprocessing market and deliver novel solutions to our clients, we are thrilled to welcome Darcy Birse to our executive team," said Will Patrick, CEO and Co-founder of Culture Biosciences.

Element Biosciences Establishes Scientific Advisory Board

Retrieved on: 
Monday, August 14, 2023

SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.

Key Points: 
  • SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.
  • Element's Scientific Advisory Board will provide guidance and direction for research, development, and product innovation as the company continues its success and expansion in the genomics industry.
  • "With this diverse and accomplished group of scientists from across the globe, our Scientific Advisory Board empowers us to reach new heights in research and product innovation," said Michael Previte, PhD, Element CTO, SVP of R&D, and co-founder.
  • "I am thrilled to lead Element's Scientific Advisory Board," said Joseph (Jody) Puglisi, Jauch Professor in the Department of Structural Biology at Stanford University School of Medicine and Element's Scientific Advisory Board chair.

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Retrieved on: 
Thursday, May 25, 2023

SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.

Key Points: 
  • SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.
  • EMBO Molecular Medicine is a SCIE (Science Citation Index Expanded) journal.
  • EMBO is a world-renowned journal with an impact factor 14.005, has a ranking of top 5%.
  • Therefore, Bersiporocin can bring antifibrotic effect through reduced enzymatic activity while still maintaining its critical function in homeostasis.

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Retrieved on: 
Thursday, May 25, 2023

SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.

Key Points: 
  • SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of Bersiporocin as an antifibrotic for idiopathic pulmonary fibrosis was published in EMBO Molecular Medicine on the 21st.
  • EMBO Molecular Medicine is a SCIE (Science Citation Index Expanded) journal.
  • EMBO is a world-renowned journal with an impact factor 14.005, has a ranking of top 5%.
  • Therefore, Bersiporocin can bring antifibrotic effect through reduced enzymatic activity while still maintaining its critical function in homeostasis.

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

Retrieved on: 
Tuesday, April 25, 2023

All candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.

Key Points: 
  • All candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • On January 6 and January 30, 2023, CureVac announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and flu.
  • As of December 31, 2022, CureVac has settled most of its financial obligations related to CVnCoV.
  • In the first quarter of 2022, CureVac received a €10 million milestone payment related to the initiation of the seasonal flu clinical trial.

Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022

Retrieved on: 
Tuesday, December 6, 2022

Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.

Key Points: 
  • Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.
  • For molecular and cell biologists, nucleic acid purification column kits are highly redundant in the global molecular market.
  • Serving these demands, TIANGEN designed the groundbreaking research oriented automated extractor: the TGuide S16, empowered by insights of scientist behaviors and expectations, the 12-year experience on automated extractors, and rich supporting reagent kit pools.
  • It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection.

Karl Friston joins VERSES as Chief Scientist to Lead New Era in Artificial Intelligence

Retrieved on: 
Thursday, December 1, 2022

It is with great enthusiasm and excitement that we welcome Karl Friston to VERSES as our Chief Scientist, said Gabriel Ren, Founder, and CEO of VERSES.

Key Points: 
  • It is with great enthusiasm and excitement that we welcome Karl Friston to VERSES as our Chief Scientist, said Gabriel Ren, Founder, and CEO of VERSES.
  • Friston who was ranked #1 most influential neuroscientist in the world by Semantic Scholar in 2016 has had an illustrious and decorated scientific career.
  • I am genuinely delighted to be working alongside Karl Friston at VERSES, said Maxwell Ramstead, Director of Research at VERSES.
  • VERSES is a cognitive computing company specializing in next-generation Artificial Intelligence.

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Thursday, December 1, 2022

Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.

Key Points: 
  • Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
  • OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells.
  • Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio.